This Week at the FDA: Opioid Crack and Orphan Drugs
Happy Halloween! As the spookiest day of the year approaches, we're highlighting FDA announcements from the last week and a half we think you should hear about. Check them out…
Happy Halloween! As the spookiest day of the year approaches, we're highlighting FDA announcements from the last week and a half we think you should hear about. Check them out…
Last time Patient Worthy wrote about Mila Makovec, she was seven and beginning a cutting-edge experimental treatment for her Batten disease. It’s now nine months later, and Mila is showing…
I live in North Carolina. where we were recently hit with a powerful hurricane that caused a lot of damage. Many trees fell on and around my house. One tree…
For some fortunate individuals, cancer is kind of a foreign concept. They obviously know what it is- they hear cancer stories in passing, they may have donated to a charity…
All things Levi. Such a generally fun-loving little boy, yet such a complex bundle of medical conflagrations. All blended and tied up in a robust package that makes Levi a…
According to a story from pm360online.com, the specialty pharmaceutical company Santhera Pharmaceuticals has recently announced of its Phase Ib/IIa clinical trial that will test its experimental product POL6014. This therapy…
According to a story from Inside Philanthropy, a recent case study was conducted in order to determine the main sources of funding for rare disease research. This broad ranging study…
According to a story from technology.org, The National Center for Advancing Translational Sciences (NCATs) has been hard at work coming up with new methods for engaging with the public and…
According to a story from globenewswire.com, Galapagos NV and Gilead Sciences, Inc., recently announced that two clinical trials which were recently published in The Lancet demonstrated that the experimental treatment filgotinib could…